Consumer Affairs Secretary Nidhi Khare urged Indian manufacturers to make quality standards central to everyday operations to boost global competitiveness. She said markets are no longer driven only by cost and scale, but by quality, safety and reliability. Her message points to stricter processes, better compliance and stronger trust as key to competing abroad.
Zydus Lifesciences says its Zydus Biologics injectable plant in Ahmedabad was inspected by the USFDA from April 27 to May 5, 2026. The audit resulted in seven observations, though the company emphasized that there were no data integrity issues. Zydus is now in discussions with the USFDA to address the findings promptly and maintain compliance.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
As global regulators tighten standards, India’s pharma industry is moving beyond its old cost advantage toward tighter compliance, quality systems, and regulatory trust. With scrutiny rising across target markets, exporters face higher expectations on documentation, testing, and manufacturing practices, pushing the $30 billion export engine to recalibrate its playbook for long term access.
A Gujarat-based NGO is urging the government to regulate nutraceuticals such as health supplements under drug regulators, not food safety authorities. The group alleges uneven product quality and unregulated pricing, arguing the current framework leaves consumers exposed. If accepted, the proposal could bring tighter standards and more transparent costs for nutraceuticals nationwide.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
